Quantitation and identification of human monocytic colony-stimulating
factor in human serum by enzyme-linked immunosorbent assay
T Hanamura, K Motoyoshi, K Yoshida, M Saito, Y Miura, T Kawashima, M Nishida and F Takaku
Central Research Laboratories, Green Cross Corporation, Osaka, Japan.
An enzyme-linked immunosorbent assay (ELISA) system for the quantitation of
human monocytic colony-stimulating factor (hM-CSF) was established, which
was based on the "dual antibody immunometric sandwich" principle using
horse and rabbit polyvalent antibodies against human urinary
colony-stimulating factor (CSF-HU). The minimal detectable level of hM-CSF
was 10 U/mL, and the assays showed good reproducibility. As measured by
this method, the average serum hM-CSF level of 20 normal adults was 540 +/-
110 U/mL (range, 300 to 800 U/mL). The peak of hM-CSF measured by ELISA was
identical to that measured by bioassay when semipurified CSF-HU was
fractionated by reversed-phase high performance liquid chromatography
(HPLC). This method detected two types of hM-CSF, which had approximate
molecular weights of 85 Kd (CSF-HU) and 45 Kd in human serum and urine; the
ratio of 85:45 Kd was very high in serum and the amounts of the two types
were nearly equal in urine. After anticancer chemotherapy, the serum hM-
CSF level of one half of the patients with hematological malignancy was
elevated according to the reduction in neutrophil number, while it was
almost in the normal range in the other half of the patients, indicating
the possibility that anticancer chemotherapy damaged the hM- CSF-producing
cells. This ELISA method may be useful for monitoring the serum hM-CSF
level after anticancer chemotherapy.
Volume 72,
Issue 3,
pp. 886-892,
09/01/1988
Copyright © 1988 by The American Society of Hematology
